Open AccessExendin-4 for Parkinson's disease
Author(s) -
Felipe Esparza Salazar,
Alma R. Lezama Toledo,
Germán Rivera-Monroy,
Cesario V. Borlongan
Publication year - 2021
Publication title -
brain circulation
Language(s) - English
Resource type - Journals
eISSN - 2455-4626
pISSN - 2394-8108
DOI - 10.4103/bc.bc_21_21
Subject(s) - exenatide , agonist , medicine , glucagon like peptide 1 receptor , disease , parkinson's disease , clinical trial , receptor , pharmacology , neuroscience , diabetes mellitus , type 2 diabetes , endocrinology , psychology
This review article discusses the preclinical evidence and clinical trials testing the use of a peptide agonist of the glucagon-like peptide (GLP) receptor that promotes insulin secretion in the animal models of and patient with Parkinson's disease (PD). In particular, we focus on the therapeutic effects of the GLP receptor agonist exendin-4, also called exenatide, in PD. The ultimate goal of this article is to provide a critical assessment of the laboratory and clinical data toward guiding the translation of exendin-4 as a clinically relevant therapeutic for PD.